NCT04027036View on ClinicalTrials.gov

Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally

PHASE2CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Polio
Interventions
BIOLOGICAL

Inactivated poliovirus vaccine in reduced doses

"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"

Trial Locations (2)

21-462867

Instituto Nacional de Saúde-Mozambique CISPOC, Maputo

Unknown

INSMozambique, Maputo

All Listed Sponsors
collaborator

World Health Organization

OTHER

lead

Instituto Nacional de Saúde, Mozambique

OTHER_GOV

NCT04027036 - Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally | Biotech Hunter | Biotech Hunter